Overview

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Status:
Terminated

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Tofacitinib